Brief: Shenzhen Hepalink Pharmaceutical Says Qtrly Net Profit Attributable RMB123.3 Mln
27/10/2021 13:19
Oct 27 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* QTRLY NET PROFIT ATTRIBUTABLE RMB123.3 MILLION, DOWN 3.29%
* QTRLY OPERATING REVENUE RMB1.52 BILLION, UP 71.83%
Source text for Eikon: ID:nHKS1mhcMf
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA